CLENPIQ

Peak

sodium picosulfate, magnesium oxide, and anhydrous citric acid

Ferring Pharmaceuticals
NDAORALSOLUTION
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3

Mechanism of Action

Acidifying Activity

Pharmacologic Class:

Calculi Dissolution Agent

Clinical Trials (3)

NCT04113382Phase 1/2Recruiting

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

Started Jun 2022
30 enrolled
Bowel Preparation
NCT04150133N/ACompleted

Effects and Tolerability With Clenpiq and Low Residue Diet

Started Nov 2019
154 enrolled
Colonoscopy Preparation
NCT03198221Phase 4Terminated

Comparison of Clenpiq vs Golytely Bowel Preparation

Started Jul 2018
14 enrolled
Bowel Preparation Solutions

Loss of Exclusivity

LOE Date
Jan 27, 2038
144 months away
Patent Expiry
Jan 27, 2038

Patent Records (4)

Patent #ExpiryTypeUse Code
10624879
Jun 23, 2034
Product
—
11191753
Jun 23, 2034
U-3261
9827231
Jun 26, 2034
Product
U-2162
12458634
Jan 27, 2038
Product
—
Company
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Argentina - Buenos Aires
128 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers